1. Inicio
  2. Publicaciones
  3. Impact of donor selection in adverse-risk AML undergoing hematopoietic cell transplantation: A study from the EBMT Acute Leukemia Working Party.

Impact of donor selection in adverse-risk AML undergoing hematopoietic cell transplantation: A study from the EBMT Acute Leukemia Working Party.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Ferhat AT
  • Gedde-Dahl T
  • Socie G
  • Huynh A
  • Blau IW
  • Yakoub-Agha I
  • Blaise D
  • Eder M
  • Forcade E
  • Fanin R
  • Passweg J
  • Crawley C
  • Stelljes M
  • Stölzel F
  • Kroeger N
  • Sengeloev H
  • Ceballos P
  • Labussiere-Wallet H
  • Poiré X
  • Esteve J
  • Savani B
  • Nagler A
  • Piemontese S
  • Mohty M
  • Ciceri F

Grupos

Abstract

We evaluated the influence of donor type in 3006 adults with adverse-risk cytogenetic acute myeloid leukemia (AML) in first complete remission undergoing allogeneic hematopoietic cell transplantation (HCT). Donor types included matched sibling (MSD), matched unrelated (MUD), mismatched unrelated (MMUD), and haploidentical donors. At 2 years, leukemia-free survival, overall survival (OS), and graft-versus-host disease (GVHD)-free/relapse-free survival were 47%, 55%, and 36%. Compared with MSD, OS was inferior with MUD (HR 1.36; 95% CI, 1.1-1.67), MMUD (HR 1.4; 95% CI, 1.07-1.83), and haploidentical grafts (HR 1.33; 95% CI, 1.02-1.73). Haploidentical was associated with lower relapse risk (HR 0.72; 95% CI, 0.53-0.97), but higher non-relapse mortality (NRM) (HR 3.85; 95% CI, 2.44-6.08). All alternative donors showed higher rates of grade II-IV acute GVHD. In 702 patients receiving post-transplant cyclophosphamide (PTCy), survival differences attenuated. However, haploidentical and MMUD showed higher risk of grade III-IV acute GVHD (HR 2.61; 95% CI, 1.04-6.54 and HR 3.74; 95% CI, 1.14-12.24), and haploidentical had increased NRM (HR 3.22; 95% CI, 1.23-8.44), without significant relapse. Findings support safety of alternative donors and reinforce MSD as preferred choice in adverse-risk AML. PTCy mitigates but does not eliminate the risk of donor mismatch.

© 2025. The Author(s), under exclusive licence to Springer Nature Limited.

Datos de la publicación

ISSN/ISSNe:
0268-3369, 1476-5365

BONE MARROW TRANSPLANTATION  SPRINGERNATURE

Tipo:
Article
Páginas:
187-196
PubMed:
41318843
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
0,998 SCImago ℠
Cuartil:
Q2 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • acute myeloid leukemia; adolescent; adult; aged; disease free survival; donor selection; female; graft versus host reaction; hematopoietic stem cell transplantation; human; male; middle aged; mortality; procedures; therapy; transplantation conditioning; young adult; Adolescent; Adult; Aged; Disease-Free Survival; Donor Selection; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Young Adult

Cita

Compartir